Curis 配当と自社株買い
配当金 基準チェック /06
Curis配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-700.9%
バイバック利回り
| 総株主利回り | -700.9% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブ更新 • Aug 04
CRIS: Future Profitability Will Depend On TakeAim CLL Study Progress
Analysts have lifted their price target on Curis to $43 from $17, citing the added valuation for emavusertib in chronic lymphocytic leukemia following the initiation of the TakeAim study and an assumed 10% probability of success on potential peak sales of $500m. Analyst Commentary Recent research on Curis highlights how much of the current valuation hinges on emavusertib and the new TakeAim study in chronic lymphocytic leukemia.ナラティブ更新 • Jul 20
CRIS: Future Profitability Execution Will Rely On TakeAim CLL Trial Progress
Analysts have sharply increased their price target on Curis, raising fair value from $14 to $280. They cite improved leadership, a more focused direct-to-consumer approach, and potential benefits from underappreciated tariff changes as key factors behind the reassessment.
ナラティブ更新 • Jul 06
CRIS: TakeAim CLL Progress Will Reshape Perceived Risk Profile
Analysts have sharply increased their price target on Curis to $400 from $20, citing a lower assumed discount rate, higher projected revenue growth, modestly stronger profit margins, and a slightly higher future P/E multiple as the key factors behind the updated view. Analyst Commentary on Curis Recent research updates on Curis signal a clear shift toward a more constructive stance, with bullish analysts pointing to a mix of valuation reset, growth potential, and improving execution as reasons to revisit the stock.分析記事 • Jul 01
Curis (NASDAQ:CRIS) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...ナラティブ更新 • Jun 22
CRIS: Future Profitability Execution Will Support Maintained 14 Fair Value
Analysts maintained their $14.00 price target for Curis, citing updated assumptions that combine a lower discount rate with higher projected revenue growth, wider profit margins and a slightly higher future P/E multiple as the main factors behind the refreshed valuation work. Analyst Commentary Recent commentary on Curis centers on how the refreshed $14.00 valuation stacks up against execution risk, profitability assumptions and the path to monetizing the company’s pipeline.
ナラティブ更新 • Jun 05
CRIS: Expanded Share Authorization And Lower P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Curis, citing updated assumptions that now include a slightly lower discount rate, a smaller expected revenue decline, a modestly higher profit margin, and a much lower future P/E multiple to support the change. Analyst Commentary Recent research on Curis points to a mixed backdrop, where some price target adjustments sit alongside a cautious tone on execution and valuation risk.ナラティブ更新 • May 11
CRIS: Expanded Share Authorization Will Support Future Upside Despite Delisting Risks
Analysts raised their price target on Curis by $5, citing updated assumptions for revenue decline, improved profit margin expectations, a slightly lower discount rate, and a reduced future P/E estimate. Analyst Commentary Analyst reactions around Curis highlight a mix of higher price targets and upgraded ratings, but also a thread of caution around how much upside is already reflected in the stock and how execution risk could affect valuation.ナラティブ更新 • Apr 24
CRIS: Expanded Share Authorization And Elevated Future P/E Will Support Upside
Analysts have raised the price target on Curis to $5.00 from $5.00, citing updated assumptions around discount rates, slightly less severe expected revenue contraction, lower profit margins, and a higher future P/E multiple. Analyst Commentary Recent Street research on peer names in the broader consumer space highlights how quickly sentiment can shift when expectations around earnings power, tariff exposure, and valuation multiples come under scrutiny.ナラティブ更新 • Apr 09
CRIS: Expanded Capital Base And Elevated Future P/E Will Support Upside
Analysts have adjusted their price target on Curis to $5.00 from $5.00, citing slightly lower discount rate and revenue decline assumptions, along with a higher future P/E multiple, as key drivers of the updated view. Analyst Commentary Bearish analysts looking at Curis are focusing on how the current valuation lines up with execution risk and the assumptions baked into the updated price target.ナラティブ更新 • Mar 26
CRIS: Expanded Capital Base And Rich Future P/E Will Support Upside
The analyst price target for Curis has been adjusted from $5 to $5.00. Analysts cite a lower discount rate, a shift to expectations of a 15.61% revenue decline, and a significantly higher assumed future P/E multiple as the main factors behind this revision.ナラティブ更新 • Mar 11
CRIS: Maintained US$14 Fair Value Will Depend On Execution Risk
Analysts have maintained their $14.00 price target on Curis while adjusting key inputs, including a slightly lower discount rate, a revised profit margin outlook, and a higher future P/E assumption to reflect updated views on execution risk and valuation support. Analyst Commentary Analysts covering Curis are focusing less on big headline calls and more on how the updated assumptions behind the $14.00 price target line up with execution risk, profitability, and valuation support.ナラティブ更新 • Feb 24
CRIS: Expanded Capital Base And Financing Structure Will Support Long-Term Upside
Narrative update on Curis The analyst price target for Curis has been lifted by $7, with analysts pointing to a slightly lower discount rate, modestly higher revenue growth expectations and a somewhat richer future P/E assumption as key drivers of the change. Analyst Commentary Recent Street research around comparable names highlights how quickly sentiment can swing when execution, growth visibility, or valuation do not line up cleanly.ナラティブ更新 • Feb 10
CRIS: Maintained US$14 Fair Value Will Rely On Clinical Progress
Analysts have kept their price target for Curis steady at US$14.00. The updated view reflects slightly lower discount rate and profit margin assumptions, which are offset by a modestly reduced future P/E multiple.ナラティブ更新 • Jan 25
CRIS: Frontline AML Data And Insider-Backed Financing Will Support Long-Term Upside
Analysts have lifted their price target on Curis to $5.00 from $5.00, citing updated assumptions around higher projected revenue growth and slightly stronger long-term profit margins, partially tempered by a higher discount rate and a lower future P/E multiple. Analyst Commentary Recent Street research on other consumer names highlights several themes that cautious investors are watching closely and that can be relevant when you think about Curis as well.ナラティブ更新 • Jan 10
CRIS: Higher Future P/E And Clinical Progress Will Support Long Term Earnings
Analysts have raised their price target on Curis to $14.00, a change they link to updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple. Analyst Commentary Analysts are applying a similar playbook across several consumer names, and that context helps explain the recent price target move on Curis.分析記事 • Jan 04
Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge
Unfortunately for some shareholders, the Curis, Inc. ( NASDAQ:CRIS ) share price has dived 27% in the last thirty days...ナラティブ更新 • Dec 25
CRIS: Frontline AML Data Will Drive Long-Term Upside Despite Heightened Risk
Analysts have cut their price target on Curis from $12.00 to $5.00 as they increase the assumed discount rate, while also lifting revenue growth expectations and lowering future valuation multiples. This reflects a more cautious yet still constructive outlook on the company’s long-term earnings power.ナラティブ更新 • Dec 11
CRIS: Reduced Risk Profile Will Support Long Term Earnings Recovery
Analysts have nudged their price target on Curis modestly higher to $14.00, citing slightly lower perceived risk and a marginally cheaper future earnings multiple. Together, these factors support a cautiously more constructive long term outlook.ナラティブ更新 • Nov 27
CRIS: Cost Efficiencies Will Drive Earnings Recovery Despite Macro Pressures
Curis's analyst price target has been raised modestly, with analysts citing improved profit margin projections and a better cost outlook as reasons for the updated valuation of $14.00 per share. Analyst Commentary Analysts recently updated their perspectives on Curis in light of the company’s latest performance and forward-looking guidance.分析記事 • Nov 20
Curis, Inc. (NASDAQ:CRIS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
The Curis, Inc. ( NASDAQ:CRIS ) share price has fared very poorly over the last month, falling by a substantial 28...ナラティブ更新 • Nov 13
CRIS: Cost-Saving Initiatives Will Support Stronger Revenue Expansion Into 2026
Curis's analyst price target has been reduced from $16.33 to $14.00. This adjustment reflects analysts' concerns over softer profit margins, even with stronger revenue growth projections and an increased discount rate.分析記事 • Aug 08
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target
NasdaqCM:CRIS 1 Year Share Price vs Fair Value Explore Curis's Fair Values from the Community and select yours Curis...
新しいナラティブ • Apr 14
FDA And EMA Will Accelerate Emavusertib Clinical Trials
Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space.分析記事 • Apr 02
Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)
Celebrations may be in order for Curis, Inc. ( NASDAQ:CRIS ) shareholders, with the analysts delivering a significant...分析記事 • Apr 01
Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30%
The Curis, Inc. ( NASDAQ:CRIS ) share price has fared very poorly over the last month, falling by a substantial 30...分析記事 • Dec 29
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Curis, Inc. ( NASDAQ:CRIS ) share price has dived 26% in the last thirty days...分析記事 • Nov 14
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Curis, Inc. ( NASDAQ:CRIS ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Aug 07
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Curis, Inc. ( NASDAQ:CRIS ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Aug 05
Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 2.9x Curis, Inc. ( NASDAQ:CRIS ) may be sending very bullish signals at the...分析記事 • Apr 03
Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Curis, Inc. ( NASDAQ:CRIS ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...決済の安定と成長
配当データの取得
安定した配当: CRISの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: CRISの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Curis 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (CRIS) | n/a |
| 市場下位25% (US) | 1.3% |
| 市場トップ25% (US) | 4.0% |
| 業界平均 (Biotechs) | 1.9% |
| アナリスト予想 (CRIS) (最長3年) | n/a |
注目すべき配当: CRISは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: CRISは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: CRISの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: CRISが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/17 10:02 |
| 終値 | 2026/08/17 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Curis, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17
| アナリスト | 機関 |
|---|---|
| Brian Skorney | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Justin Walsh | B. Riley Securities, Inc. |